Medical News

RSS

Impax initiates challenge of patents relating to WELCHOL

Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by Daiichi Sankyo, Inc. in connection with its WELCHOL® (Colesevelam HCl) for Oral Suspension, 3.75 gm/packet and 1.875 gm/packet.

22 Nov 2010

Research roundup: Health IT and malpractice; Wide variation in hospital rates; Income and insurance offerings

New England Journal of Medicine: Medical Malpractice Liability In The Age Of Electronic Health Records - "Providers can expect a varied and shifting landscape of medical liability risks and benefits as the adoption of [electronic health records] EHRs unfolds," write the authors who explore the ways EHRs may bring about long-term changes in standard of care and affect the course of malpractice litigation.

22 Nov 2010

Humana to acquire Concentra for $790 million

Humana Inc. today announced it has signed a definitive agreement to purchase Concentra Inc., a privately held health care company based in Addison, Texas, for approximately $790 million in cash. Through its affiliated clinicians, Concentra delivers occupational medicine, urgent care, physical therapy and wellness services to workers and the general public from more than 300 medical centers in 42 states.

22 Nov 2010

FDA grants Impax tentative approval for generic Cymbalta NDA

Impax Laboratories, Inc. confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application for generic version of Cymbalta® delayed-release (duloxetine hydrochloride) 20, 30 and 60 mg capsules.

22 Nov 2010

Political cartoon: 'Waivers'

Kaiser Health News provides a fresh look at health policy developments with 'Waivers' by Lisa Benson.

22 Nov 2010

BioPharm Asia third quarter revenue increases 68% to $44.7 million

BioPharm Asia, Inc., a producer, distributor and retailer of medical products in China, today announced its financial results for the three months and nine months ended September 30, 2010.

22 Nov 2010

KHN column: The Roadmap lives

In his latest Kaiser Health News column, James Capretta writes: "Last year, Rep. Paul Ryan's 'Roadmap' -- his far-reaching plan to restore long-term budget balance through tax and entitlement reform -- was the subject of relentless attacks by those favoring a larger government role in American life. New York Times columnist Paul Krugman called Ryan the 'Flimflam Man' in a widely cited opinion piece in which he tried to dismiss the Roadmap as not a credible solution to the nation's budget problems.

22 Nov 2010

Neurocrine announces results from elagolix Phase II Daisy PETAL study in endometriosis

Neurocrine Biosciences, Inc. today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

22 Nov 2010

Cerner products achieve CCHIT Complete EHR certification

Cerner Corporation announced today that PowerChart®, FirstNet®, ProFile®, HealthSentry®, Cerner Healthe, Cerner® Health Record, IQHealth® and P2Sentinel™ 2007.19.12 and P2Sentinel™ v4.2.1 is 2011/2012 compliant and was certified as a Complete EHR on Oct.28, 2010 by the Certification Commission for Health Information Technology, an Office of the National Coordinator for Health Information Technology - Authorized Testing Certification Bodies, in accordance with the applicable Hospital certification criteria adopted by the Secretary of Health and Human Services.

22 Nov 2010

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.

22 Nov 2010

Helpson receives 'National High-Tech Enterprise' status

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd ("Helpson"), received the "National High-Tech Enterprise" status ("National HT Status") from the PRC government, as recognized by the Ministry of Science and Technology of China, the Ministry of Finance, and the State Administration of Taxation.

22 Nov 2010

Mimetogen initiates MIM-D3 Phase II clinical trial for dry eye disease

Mimetogen Pharmaceuticals Inc., a clinical-stage biotechnology company focused on developing novel small molecule compounds that mimic the effects of neurotrophins, today announced that it has initiated the first human clinical trial evaluating MIM-D3, a mimetic of nerve growth factor (NGF), in a Phase II clinical trial in patients with moderate to severe dry eye disease. MIM-D3 is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye that is responsible for the maintenance of corneal nerves and epithelium, mucin and tear production.

22 Nov 2010

UAHC first quarter revenues increase 20.3% to $2.1 million

United American Healthcare Corporation today announced financial results for the Company's fiscal first quarter ended Sept. 30, 2010, which included higher revenues and improved bottom line results.

22 Nov 2010

Profil Institute expands capabilities to detect cardiac safety signals in diabetes and obesity clinical trials

Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company's early phase diabetes and obesity clinical trials.

22 Nov 2010

Pfizer subsidiary extends tender offer for King acquisition

Pfizer Inc. today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

22 Nov 2010

Grifols launches Flebogamma 10% DIF intravenous immune globulin in the U.S.

Grifols today announced availability of its recently approved Flebogamma® 10% DIF intravenous immune globulin. Grifols is a global healthcare company specializing in bioscience medicines derived from human plasma. Approval from the US Food and Drug Administration (FDA) for Flebogamma® 10% DIF was obtained in July 2010 and final approval in Europe is expected before the end of the year. Today's announcement signals widespread product availability to the US market.

22 Nov 2010

Cyberonics second quarter net sales increase 17% to $47.5 million

Cyberonics, Inc. today announced results for the quarter ended October 29, 2010.

22 Nov 2010

Medisafe 1 Technologies to develop new medical locking devices for intravenous administration

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that that the company's board of directors has approved the research and development of two new medical locking device products.

22 Nov 2010

$S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies$

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.

22 Nov 2010

Medworxx Bed Optimization System goes live across St. Michael's Hospital

Medworxx Inc., provider of healthcare solutions for patient flow, compliance and education, announced today that St. Michael's Hospital is now live on the Medworxx Bed Optimization System (BOS). Medworxx BOS is now live across St. Michael's Hospital, helping to manage 460 beds.

22 Nov 2010